logo
  

Arena Pharma's Atopic Dermatitis Drug Fails To Meet Primary Endpoint, Stock Down 20%

Shares of Arena Pharmaceuticals, Inc. (ARNA) plunged 20% in extended session Monday after it skin inflammation drug failed to meet primary endpoint in a mid-stage trial.

Arena Pharmaceuticals announced topline results from the Phase 2b ADVISE clinical trial evaluating etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate receptor modulator, for the treatment of moderate-to-severe atopic dermatitis.

The company said etrasimod did not meet the trial's primary endpoint of Eczema Area and Severity Index change from baseline at week 12.

In the primary analysis of the trial, nearly one-third of participants in the 2 mg etrasimod group achieved clear or almost clear skin, as defined by the validated Investigator Global Assessment, which is the FDA endpoint for Phase 3 registration. The vIGA improvement was statistically significant compared to placebo at 12 weeks. Across the Eczema Area and Severity Index, EASI-75 and peak change in pruritis, etrasimod 2 mg demonstrated early and statistically significant effect at week 4.

Atopic dermatitis usually develops in early childhood and is more common in people who have a family history of the condition. The main symptom is a rash that typically appears on the arms and behind the knees, but can also appear anywhere. Treatment includes avoiding soap and other irritants. Certain creams or ointments may also provide relief from the itching.

ARNA closed Monday's trading at $87.42, up $0.78 or 0.90%, on the Nasdaq. The stock, however, slipped $17.42 or 19.93%, in the after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Oilfield services company Schlumberger Ltd. reported Friday a profit for the fourth quarter that surged 61 percent from last year, reflecting 13 percent higher revenues amid growth across all segments and regions. Both adjusted earnings per share and quarterly revenues topped analysts' estimates. Twitter Inc. has launched a new feature to allow some users of its Blue subscriber service to keep non-fungible tokens or NFTs as their profile pictures. Twitter Blue is now available in the US, Canada, Australia, and New Zealand. NFT is a crypto token, which is non-fungible, meaning that it can neither be transferred like money nor replaced with something else. Frozen Food Development is recalling specific lots of Lidl branded 12-ounce packages of Frozen Chopped Spinach citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The product comes in 12-ounce poly bags, and items included in the recall are marked with lot # R17742 or R17963 on the back of the poly bag with a best by date of 09/10/23.
RELATED NEWS
Follow RTT